TickerTalks
Browse all tickers →
TickerTalks›$EW
EWEW

Edwards Lifesciences Corporation

Strong FundamentalsStrong FundamentalsRevenue growing 14% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (234/wk), no spike
$EW·$48B·Medical - Devices·Healthcare
$83.68+0.8%YTD-2.8%1Y+5.8%
Mentions · last 7 days
2026-07-21: 21 posts2026-07-22: 7 posts2026-07-23: 71 posts2026-07-24: 62 posts2026-07-25: 22 posts2026-07-26: 27 posts2026-07-27: 24 posts234+12%
Price updated 5m ago·X counts updated 23h ago
EWEW
$EWEdwards Lifesciences Corporation
$83.68+0.77%234 posts+12%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $EW, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Edwards Lifesciences delivered Q2 beat and MedTech tailwinds — the TAVR-plus-newer-programs setup is intact if the tape recovers from officer selling.

Edwards Lifesciences is the market leader in transcatheter aortic valve replacement (TAVR) with the Sapien portfolio, plus a growing surgical structural heart and critical care franchise. Q2 delivered a revenue beat with $1.74B (vs $1.70B est) and adjusted EPS of $0.78 vs $0.74 est, adding to a bullish MedTech thesis.

The setup is a mature MedTech compounder with legitimate operational strength:

  • The Q2 print validates the fundamentals: quarterly revenue climbed from $1.55B to $1.74B and EPS from $0.16 to $0.66 (with Q4 seasonal), and the beat plus commentary on the surgical structural heart and critical care segments extends the multi-year 8-10% growth compounder narrative — consensus FY26 revenue of $6.76B growing to $7.43B in FY27.
  • Valuation is elevated but defensible: 47x TTM P/E and 7.3x sales on a business with expanding operating margins is priced for continued execution — the 4-quarter beat streak (+5% to +19% surprises) says the business consistently beats consensus.
  • Insider selling is the material caveat: nine insider events including officer Zovighian's $245K S-Sale plus a G-Gift on July 27, and officer Lippis's $57K sale on July 10 — meaningful officer activity clustered right after the print, exactly the pattern that keeps a lid on how far a beat can run.

The tape at 43rd percentile of 52-week range says the market isn't fully repricing the beat yet. The Oct 29 print is the reset lever — continued TAVR growth plus newer program updates extends the compounder narrative; anything soft on international mix or gross margin and the 47x TTM multiple compresses. Real business with real insider distribution overhang.

Agrees with X sentimentX is right that Edwards Q2 delivered a real beat validating the MedTech bullish thesis — analysts calling it fuel for continued outperformance have substance given the streak of positive surprises. The honest add: the July 10-27 officer S-Sale cluster (Zovighian, Bruls, Lippis) is worth flagging as a real insider signal even if not distributional enough to break the tape.

What to watch: Oct 29 Q3 earnings — TAVR unit growth, surgical structural heart segment, international/OUS growth, and any updated FY guide. A TAVR beat plus expanded international commentary extends the setup; anything soft on international mix and the 47x multiple compresses.

On the calendar: 2026-10-29 — Q3 earnings

Read the AI verdict + X sentiment for $EW

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $EW.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

Industry benchmark

18-name peer basket
-9.7%YTD
-4.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
47.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
10.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
28.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
7.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
9.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
78.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 23, 2026$0.78$0.74+5.0%
Q1 2026Apr 23, 2026$0.78$0.73+7.0%
Q4 2025Feb 10, 2026$0.58$0.62-6.1%
Q3 2025Oct 30, 2025$0.67$0.60+12.4%
Next earningsThu, Oct 29·consensus EPS $0.73

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$1.7B+13.6%77.6%29.8%$0.42—
Q1 FY26$1.6B+16.7%78.2%31.2%$0.66$-21.1M
Q4 FY25$1.6B+13.3%78.3%23.6%$0.16$353.5M
Q3 FY25$1.6B+14.7%77.9%27.4%$0.50$516.2M

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$6.8B$6.6B – $6.8B$3.00$2.96 – $3.0221
FY27$7.4B$7.2B – $7.5B$3.38$3.32 – $3.5021
FY28$8.2B$7.8B – $8.5B$3.79$3.69 – $3.8921
FY29$8.9B$8.7B – $9.1B$4.18$4.02 – $4.2810
FY30$9.8B$9.5B – $10.0B$4.61$4.43 – $4.7210

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.43%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-1.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 27Bernard J ZovighianCEO2.9K sh$245KSellJul 10Daniel J. LippisCVP, TAVR619 sh$57KSellJun 30Daniel J. LippisCVP, TAVR619 sh$57KSellJun 17Bernard J ZovighianCEO523 sh$46KSellMay 29Andrew M. DahlSVP, Corporate Controller568 sh$49KSellMay 27Donald E BoboCVP,Strategy/Corp Development23.1K sh$2.0MSellMay 22Daveen ChopraCVP, TMTT & Surgical1.5K sh$127KSellMay 18Daniel J. LippisCVP, TAVR620 sh$50KSellMay 15Donald E BoboCVP,Strategy/Corp Development18.0K sh$1.5MSellMay 12Bernard J ZovighianCEO36.4K sh$2.8M
1–10 of 11
+ 24 other (10 inkinds · 7 exempts · 4 gifts · 3 awards) in window

See when $EW insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Saysbenzinga.com·4d agoEdwards' Q2 Earnings & Revenues Top Estimates, Stock Riseszacks.com·4d agoEdwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancementsgurufocus.com·5d agoEdwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcriptseekingalpha.com·5d agoEdwards Lifesciences Q2 Earnings Call Highlightsmarketbeat.com·5d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ISRG$MDT$BIO$TMDX$BSX$ABT$NVCR$BFLY
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport